Crinecerfont

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Congenital Adrenal Hyperplasia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Congenital Adrenal Hyperplasia
NCT07947368 · Neurocrine Biosciences
2026-11 – 2028-07 · Congenital Adrenal Hyperplasia
What this study did
Phase 2 (4)
Congenital Adrenal Hyperplasia
NCT07187375 · Neurocrine Switzerland GmbH
2025-09-30 – 2029-10-04 · Congenital Adrenal Hyperplasia
What this study did
NCT07536269 · Neurocrine Switzerland GmbH
2026-07-01 – 2028-03 · Congenital Adrenal Hyperplasia
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Crinecerfont to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (2)
January 2028 (1)
Phase 3Congenital Adrenal HyperplasiaNot yet recruiting
Est. primary completion 2028-01 · NCT07947368 · CT.gov ↗
What to watch
March 2028 (1)
Phase 2Congenital Adrenal HyperplasiaRecruiting
Est. primary completion 2028-03 · NCT07536269 · CT.gov ↗
What to watch
2029 (1)
September 2029 (1)
Phase 2Congenital Adrenal HyperplasiaActive not recruiting
Est. primary completion 2029-09-06 · NCT07187375 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

13 December 2024ApprovalFDA approves CRENESSITY for classic CAH
US, FDA · Source ↗